findinEsegui ricerca

Newsletter 2, January 2014

Understanding your counterparties in technology transfer and healthcare innovation.
EditorialChristian Suojanen
Co-Founder - TTS Global Initiative
Chairman of the ENTENTE Industry Advisory Board
Over the past several years, there has been a growing focus on and prioritization of technology transfer as a key component in the innovation value chain of the biotech, pharma and healthcare sectors. While many factors have impacted this, perhaps the key driver has been the change in the pharma industry drug discovery and development innovation paradigm.

While Thomas Kuhn’s concept of a paradigm shift is commonly misused to describe any change in processes, it must be agreed that the changes in how the pharma industry innovates are nothing short of fundamental, and might not have taken place in the absence of the patent cliff that forced big pharma to re-evaluate their entire approach to drug discovery and development. The resulting emphasis on external R&D and collaborative innovation provides not only enormous strategic opportunity to research institutes to engage with industry in more systemic, strategic collaborations than were previously possibly, but have also result in ever increasing demands on technology transfer, licensing and commercialization offices to become expert in much more than the traditional tools of patenting, intellectual property management, and licensing.

See more

Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies Testimonies
"I'm very glad to be part of ENTENTE Professional Exchange Program that focuses heavily on the dynamics within the knowledge transfer offices in the health sector. The knowledge transfer from research community to the industry is one of the main factors to boost and sustain the competitiveness of the modern economy."
New drug relieves cancer patients
When Horst Lindhofer started research on bispecific antibodies in cancer treatment, he could not have expected that many years later, the drug developed from this research would be so beneficial to cancer patients. The drug, called Removab, inhibits painful fluid build-up in the abdomen.
When a virus creates jobs

Expanding views with 3D microscopes
InterviewBring your research results to the market

InterviewJoin knowledge transfer community

InterviewGet prepared for Horizon 2020
3 March 2014 - IE Business School, Madrid (Spain)
Cutting Edge Decision Making Tools for Entrepreneurs

10-14 March 2014 - University of Gothenburg, Gothenburg (Sweden)
Intellectual Property, Ethics & the Utilization of Academic Research in health/life sciences

Do you want to receive the next Entente Newsletters?join our community
Do you want to receive the next Entente Newsletters?join our community
This project has received funding from the European Union’s Seventh Programme for 
research, technological development and demonstration under grant agreement No 305128
  ENTENTE is supported by the European Commission and coordinated by Inserm-Transfert SA